|Mr. Gil Beyen BVBA||CEO & Director||456.42k||N/A||1962|
|Mr. Jérôme Bailly Pharm.D.||VP, Director of Pharmaceutical Operations & Deputy GM||234.28k||N/A||1979|
|Mr. Eric Soyer Ph.D.||CFO, COO & Deputy GM||N/A||N/A||1966|
|Dr. Alexander Scheer||Chief Scientific Officer||N/A||N/A||1962|
|Naomi Eichenbaum||Director Investor Relations||N/A||N/A||N/A|
ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for severe forms of cancer and orphan diseases. The company's lead product candidate is eryaspase, which is in Phase III clinical development for the treatment of second-line pancreatic cancer and in Phase II stage for the treatment of triple-negative breast cancer. ERYTECH Pharma S.A. has research collaboration with the Fox Chase Cancer Center to advance the preclinical development of erymethionase for the treatment of homocystinuria; and Queen's University of Canada to advance the preclinical development of eryminase for the treatment of arginase-1-deficiency. ERYTECH Pharma S.A. was founded in 2004 and is headquartered in Lyon, France.
ERYTECH Pharma S.A.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.